Evidence map›Paper›PMID 26503034›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2016

The Role of Stage at Diagnosis in Colorectal Cancer Black-White Survival Disparities: A Counterfactual Causal Inference Approach.

Linda Valeri, Jarvis T Chen, Xabier Garcia-Albeniz, Nancy Krieger, Tyler J VanderWeele, Brent A Coull

Abstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Age-dependent prognostic value ofFuture oncology (London, England) · 2021
    Article
  12. Article
  13. Examining COVID-19 Preventive Behaviors among Cancer Survivors in the United States: An Analysis of the COVID-19 Impact Survey.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020
    Article
  14. The Impact of KRAS Mutation on the Presentation and Prognosis of Non-Metastatic Colon Cancer: an Analysis from the National Cancer Database.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2020
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Linda ValeriPsychiatric Biostatistics Laboratory, McLean Hospital, Belmont, Massachusetts. Harvard Medical School, Boston, Massachusetts. lvaleri@mclean.harvard.edu.
Jarvis T ChenDepartment of Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Xabier Garcia-AlbenizDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Nancy KriegerDepartment of Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Tyler J VanderWeeleDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Brent A CoullDepartment of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI AMY TRENTHAM-DIETZ · 1985 to 2026
$142.6M
Vermont Center on Behavior and HealthP20GM103644 · NIGMS · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI KHADANGA, SHERRIE · 2013 to 2022
$21.3M
Statistical Methods for Analysis of Massive Genetic and Genomic Data in Cancer ResearchR35CA197449 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI XIHONG LIN · 2015 to 2026
$10.9M
TRAINING AND CAREER DEVELOPMENTP50CA148596 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI SORENSEN, GLORIAN C · 2010 to 2014
$10.7M
Statistical Methods for the Spatio-Temporal Assessment of Social Disparities in CancerP01CA134294 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI HANEUSE, SEBASTIEN, HERNAN, MIGUEL · 2008 to 2017
$6.8M
Vermont Screening Process Documentation UnitU54CA163303 · NCI · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI SPRAGUE, BRIAN L · 2011 to 2017
$6.4M
RISK FACTORS AND BIOMARKERS FOR IN SITU BREAST CANCERR01CA067264 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI TRENTHAM-DIETZ, AMY · 1996 to 2013
$3.6M
Identification and Inference for Longitudinal Causal Mediation Analysis in HIVR01AI104459 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI SHPITSER, ILYA, VANDERWEELE, TYLER · 2013 to 2017
$2.0M
Theory and methods for sufficient cause interactionsR01ES017876 · NIEHS · HARVARD SCHOOL OF PUBLIC HEALTH · PI VANDERWEELE, TYLER · 2010 to 2014
$1.2M
Theory and methods for interactionR56ES017876 · NIEHS · HARVARD SCHOOL OF PUBLIC HEALTH · PI TCHETGEN TCHETGEN, ERIC JOEL, VANDERWEELE, TYLER · 2016 to 2016
$150k
NCI NIH HHS P01 CA134294NCI NIH HHS P30 CA014520NCI NIH HHS P50 CA148596NCI NIH HHS R01 CA067264NCI NIH HHS R35 CA197449NCI NIH HHS U54CA163303NIAID NIH HHS R01 AI104459NIEHS NIH HHS R01 ES017876NIEHS NIH HHS R56 ES017876NIGMS NIH HHS P20 GM103644
6 · The paper itself

Abstract

backgroundTo date, a counterfactual framework has not been used to study determinants of social inequalities in cancer. Considering the case of colorectal cancer, for which racial/ethnic differences in stage at diagnosis and survival are well documented, we quantify the extent to which black versus white survival disparities would be reduced had disparities in stage at diagnosis been eliminated in a large patient population.

methodsWe obtained data on colorectal cancer patients (diagnosed between 1992 and 2005 and followed until 2010) from US-SEER (Surveillance, Epidemiology, and End Results) cancer registries. We employed a counterfactual approach to estimate the mean survival time up to the 60th month since diagnosis for black colorectal cancer patients had black-white disparities in stage at diagnosis been eliminated.

resultsBlack patients survive approximately 4.0 [confidence interval (CI), 4.6-3.2] months less than white patients within five years since diagnosis. Had disparities in stage at diagnosis been eliminated, survival disparities decrease to 2.6 (CI, 3.4-1.7) months, an approximately 35% reduction. For patients diagnosed after the age of 65 years, disparities would be halved, while reduction of approximately 30% is estimated for younger patients. Survival disparities would be reduced by approximately 44% for women and approximately 26% for men.

conclusionsEmploying a counterfactual approach and allowing for heterogeneities in black-white disparities across patients' characteristics, we give robust evidence that elimination of disparities in stage at diagnosis contributes to a substantial reduction in survival disparities in colorectal cancer. IMPACT: We provide the first evidence in the SEER population that elimination of inequities in stage at diagnosis might lead to larger reductions in survival disparities among elderly and women.

Indexed as

Healthcare DisparitiesHealth Status DisparitiesAgedBlack or African AmericanCohort StudiesColorectal NeoplasmsFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasm StagingPrognosisSEER ProgramSurvival RateWhite People

Identifiers

PMID26503034
PMCPMC4713332

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.